N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-N'-[(6-fluoro-3'-{[4-(2-hydroxyethyl)-1-piperazinyl]methyl}-3-biphenylyl)methyl]-1,3-benzenedicarboxamide | 1177560-85-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-N'-[(6-fluoro-3'-{[4-(2-hydroxyethyl)-1-piperazinyl]methyl}-3-biphenylyl)methyl]-1,3-benzenedicarboxamide
• 英文别名: 3-N-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-1-N-[[4-fluoro-3-[3-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]phenyl]phenyl]methyl]benzene-1,3-dicarboxamide
• CAS: 1177560-85-8
• 化学式: C₄₄H₅₃FN₈O₄
• 分子量: 776.954
• InChiKey: IZQGTRQEHPWONA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  57
• 可旋转键数：
  15
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  137
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• Dual Pharmacophores - PDE4-Muscarinic Antagonistics
  申请人：Callahan James Francis

  公开号：US20090197871A1

  公开（公告）日：2009-08-06

  The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

  本发明涉及式(I)的新化合物，药物组合物及其在治疗中的应用，例如作为磷酸二酯酶IV (PDE4)的抑制剂和毒蕈碱乙酰胆碱受体 (mAChRs)的拮抗剂，用于治疗和/或预防呼吸道疾病，包括抗炎症和/或过敏性疾病，如慢性阻塞性肺病 (COPD)、哮喘、鼻炎 (例如过敏性鼻炎)、特应性皮炎或银屑病。
• US8067408B2
  申请人：——

  公开号：US8067408B2

  公开（公告）日：2011-11-29
• [EN] DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS<br/>[FR] PHARMACOPHORES DUALS, ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES ET INHIBITEURS DE L'ACTIVITÉ PDE4
  申请人：GLAXO GROUP LTD

  公开号：WO2009100168A1

  公开（公告）日：2009-08-13

  The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/ and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.